Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Dirk Huebner"'
Autor:
Huifeng Niu, Hyunjin Shin, Feng Gao, Jacob Zhang, Brittany Bahamon, Hadi Danaee, Bohuslav Melichar, Russell J. Schilder, Robert L. Coleman, Gerald Falchook, Antoine Adenis, Kian Behbakht, Angela DeMichele, Elizabeth Claire Dees, Kimberly Perez, Ursula Matulonis, Piotr Sawrycki, Dirk Huebner, Jeffrey Ecsedy
Publikováno v:
EBioMedicine, Vol 25, Iss C, Pp 50-57 (2017)
Background: Alisertib (MLN8237) is an investigational, oral, selective Aurora A kinase inhibitor. Aurora A contains two functional single nucleotide polymorphisms (SNPs; codon 31 [F/I] and codon 57 [V/I]) that lead to functional changes. This study i
Externí odkaz:
https://doaj.org/article/24f33928b1e74afda898de75f7832eaf
Autor:
Justin Watts, Michael Maris, Tara L. Lin, Prapti Patel, Yazan F. Madanat, Christopher R. Cogle, Gautam Borthakur, Dirk Huebner, Noor Khaskhely, Lynn Bonham, Monica Massaro, Daphne Taylor, Caroline Taromino, Alice S. Mims
Publikováno v:
Blood. 140:6204-6205
Autor:
Paul J Bröckelmann, Mehul Dalal, Timothy M Illidge, Dirk Huebner, Kerstin Mueller, Suzanne McMullen, Ashish Gautam, Erin Zagadailov, J Ben Wilson, Aspasia Stamatoullas, Sarah Goring
Publikováno v:
British Journal of Haematology
Bröckelmann, P J, Mcmullen, S, Wilson, J B, Mueller, K, Goring, S, Stamatoullas, A, Zagadailov, E, Gautam, A, Huebner, D, Dalal, M & Illidge, T 2019, ' Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom ', British Journal of Haematology, vol. 184, no. 2, pp. 202-214 . https://doi.org/10.1111/bjh.15566
Bröckelmann, P J, Mcmullen, S, Wilson, J B, Mueller, K, Goring, S, Stamatoullas, A, Zagadailov, E, Gautam, A, Huebner, D, Dalal, M & Illidge, T 2019, ' Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom ', British Journal of Haematology, vol. 184, no. 2, pp. 202-214 . https://doi.org/10.1111/bjh.15566
Summary First‐line treatments for classical Hodgkin lymphoma (HL) include ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and BEACOPP escalated (escalated dose bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, pr
Creating a digital twin should be easy and intuitive. This book presents twins from different technical fields and describes in detail how to build them. The book is aimed at students or young engineers who want develop and modify the twins without m
Autor:
Emily Sheldon-Waniga, Diane R. Mould, Takatoshi Takubo, Xiaofei Zhou, Karthik Venkatakrishnan, Ashley Milton, Dirk Huebner
Publikováno v:
British Journal of Clinical Pharmacology. 84:35-51
Aims This population pharmacokinetic analysis was conducted to describe quantitatively the regional differences and sources of interpatient variability on the apparent oral clearance of alisertib. Methods A population pharmacokinetic analysis was per
Autor:
Karthik Venkatakrishnan, Daniel B. Goodman, John Sarantopoulos, Manish Patel, A. Craig Lockhart, John Nemunaitis, Shubham Pant, Xiaofei Zhou, Diane R. Mould, Todd M. Bauer, Dirk Huebner
Publikováno v:
Investigational New Drugs
SummaryAims A primary objective of this study was to investigate the effect of single and multiple doses of alisertib, an investigational Aurora A kinase inhibitor, on the QTc interval in patients with advanced malignancies. The dose regimen used was
Autor:
H Miles Prince, Youn H Kim, Steven M Horwitz, Reinhard Dummer, Julia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, Jose A Sanches, Pablo L Ortiz-Romero, Oleg E Akilov, Larisa Geskin, Judith Trotman, Kerry Taylor, Stephane Dalle, Michael Weichenthal, Jan Walewski, David Fisher, Brigitte Dréno, Rudolf Stadler, Tatyana Feldman, Timothy M Kuzel, Yinghui Wang, Maria Corinna Palanca-Wessels, Erin Zagadailov, William L Trepicchio, Wenwen Zhang, Hui-Min Lin, Yi Liu, Dirk Huebner, Meredith Little, Sean Whittaker, Madeleine Duvic, David Joske, H. Miles Prince, Ian D. Lewis, Constanze Jonak, Franz Trautinger, Oliver Bechter, Dominique Bron, Vladmir Claudio C. de Lima, Jose Antonio Sanches, Richard Klasa, Martine Bagot, Marie Beylot-Barry, Michel D'Incan, Brigitte Dreno, Florent Grange, Jan Nicolay, Marion Wobser, Chalid Assaf, Carmen Loquai, Michele Spina, Alberto Bosi, Pier Paolo Fattori, Aleksandra Grzanka, Andres Lopez-Hernandez, Pablo L. Ortiz-Romero, Jose Juan Rifon Roca, Silvana Novelli Canales, Timothy Illidge, Rod Johnson, Stephen Morris, Pam McKay, Oleg Akilov, Steve Horwitz, Youn H. Kim, Barbara Pro, Timothy Kuzel, Adam Lerner, Herbert Eradat, Lubomir Sokol, David C. Fisher, Sarah Hughey
Publikováno v:
The Lancet. 390:555-566
Cutaneous T-cell lymphomas are rare, generally incurable, and associated with reduced quality of life. Present systemic therapies rarely provide reliable and durable responses. We aimed to assess efficacy and safety of brentuximab vedotin versus conv
Autor:
Vijayveer Bonthapally, Akshara Richhariya, Jeremy Teasell, Shih-Yuan Lee, Ashish Gautam, Yanyan Zhu, Esprit Ma, Dirk Huebner, Erin Zagadailov
Publikováno v:
Leukemia & Lymphoma. 59:69-76
The number needed to treat (NNT) with brentuximab vedotin consolidation therapy post-autologous stem cell transplant (ASCT) versus placebo in the phase 3 AETHERA trial to avoid one additional event of disease progression/death was evaluated. AETHERA
Autor:
Dirk Huebner, Emily K. Larsen, Scott E. Smith, Joseph D. Rosenblatt, Stephen M. Ansell, Joseph M. Connors, Ajay K. Gopal, Anas Younes, Kerry J. Savage, Robert T. Chen, Abraham P. Fong, Andreas Engert
Publikováno v:
Blood. 128:1562-1566
Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed hematopoietic autologous stem cell transplantation. At 5 years, the
Autor:
Anthony W. Tolcher, Ursula A. Matulonis, Debra L. Richardson, Michelle Cyr, W Jeffrey Edenfield, Timothy F. Burns, Susanna Varkey Ulahannan, Kyriakos P. Papadopoulos, Dirk Huebner, Rebecca Mosher, Erika Hamilton, Greg Pennock, Donna Jarlenski, Kathleen N. Moore
Publikováno v:
Gynecologic Oncology. 159:52